Inflammation, Depression, and the Gut-Brain Axis

Author's Note

This paper exists because we watched the wrong people get blamed.

A woman sits in a GP's office. She hasn't slept properly in months. Her joints ache. She can't think clearly. She has a feeling she describes as heaviness — not sadness exactly, more like her body is made of concrete. She's been eating what she can afford, which is mostly packaged food from the middle aisles of the supermarket, because the rent took everything else. She works 40 hours a week at a job that treats her like furniture. She hasn't seen her friends in weeks because there's no time, no money, and no energy. Her gut has been wrong for as long as she can remember.

The GP writes a prescription for an SSRI. The explanation: your brain doesn't make enough serotonin. The implication: the problem is in your head.

That explanation is wrong. Not partially wrong. Not oversimplified. Wrong. The most comprehensive review of the serotonin hypothesis ever conducted — Moncrieff et al., 2022, published in Molecular Psychiatry — found no consistent evidence that people with depression have lower serotonin activity than people without depression. Thirty years of public health messaging, pharmaceutical advertising, and clinical practice built on a foundation that the evidence does not support.

But here is what the evidence does support: what that woman is experiencing is an inflammatory response. Her body is inflamed. The ultra-processed food is inflamed. Her gut microbiome is disrupted. The disrupted gut is sending inflammatory signals through the vagus nerve directly to her brain. The chronic stress of precarious work and social isolation is activating her HPA axis, which is driving more inflammation. The inflammation is crossing her blood-brain barrier, activating her brain's immune cells, diverting tryptophan away from serotonin production and toward neurotoxic metabolites. She feels like concrete because her body IS in a state of systemic emergency. The depression is not a malfunction. It is her body accurately reporting its condition.

This connects directly to two of the 14 goals that drive this research:

Goal 10 — Food contains only things proven safe. The food system is making people mentally ill. Not metaphorically. Measurably. Emulsifiers in processed food disrupt the gut microbiome (Chassaing et al., 2015). Dietary advanced glycation end-products drive the same inflammatory pathways — CRP, IL-6, NF-kB — that are elevated in depression. Ultra-processed food consumption is dose-dependently associated with depression risk. The precautionary principle applied to what we eat is not a lifestyle preference. It is a mental health intervention.

Goal 14 — Cancer is 90% preventable. Here's how. Depression and cancer share the same underlying biology. Chronic systemic inflammation drives both. The same inflammatory markers — CRP, IL-6, TNF-alpha — are elevated in both conditions. The same dietary patterns that increase depression risk increase cancer risk. The same interventions that reduce inflammation reduce risk of both. If you separate depression funding from cancer funding, you miss the fact that they are the same fire burning in different rooms of the same house.

The thesis of this paper is simple and the evidence is overwhelming: depression is not a chemical imbalance. It is an inflammatory response to environmental conditions — food, isolation, stress, sedentary confinement, gut dysbiosis. The gut-brain axis connects food toxicology directly to mental health. The system that feeds you is the system that breaks you. And the people who profit from the food that inflames you also profit from the pills that mask the inflammation.

This is not a conspiracy theory. It is a supply chain.

Abstract

The serotonin deficit hypothesis of depression — the claim that depression results from insufficient serotonin activity in the brain — has been the dominant public and clinical explanation for major depressive disorder for over three decades. In 2022, Moncrieff et al. published a systematic umbrella review in Molecular Psychiatry examining every major line of evidence for this hypothesis. The result was unambiguous: there is no consistent evidence that people with depression have lower serotonin activity than people without depression. The hypothesis, as a causal explanation, is not supported.

This paper synthesises the evidence for an alternative framework: depression, or a clinically significant subtype representing approximately 25-50% of cases, is a systemic inflammatory condition with strong gut-brain involvement. We review: (1) the collapse of the serotonin hypothesis; (2) the inflammatory model of depression, including the role of CRP, IL-6, TNF-alpha, and the kynurenine pathway; (3) the gut-brain axis, including gut serotonin production, microbial regulation, and vagal communication; (4) Damasio's somatic marker hypothesis and the embodied cognition framework; (5) psychedelic research and default mode network disruption; (6) the biopsychosocial model and its implementation gap; and (7) the structural factors — food systems, work conditions, social architecture — that generate the inflammation in the first place.

The central argument is that depression is not a brain malfunction to be corrected pharmacologically. It is a whole-body state generated by environmental conditions — conditions that are modifiable. The same inflammatory pathways implicated in depression are implicated in cardiovascular disease, type 2 diabetes, autoimmune conditions, and cancer. A society that redesigns its food systems, work structures, physical environments, and community architecture is not choosing between preventing cancer and preventing depression. It is addressing the same underlying biology.

Keywords: depression, inflammation, gut-brain axis, serotonin hypothesis, microbiome, vagus nerve, cytokines, ultra-processed food, default mode network, psilocybin, biopsychosocial model, environmental determinants of health

Table of Contents

1. 1. The Serotonin Story Falls Apart
2. 2. Depression as Inflammation
3. 3. The Gut-Brain Axis
4. 4. Emotions as Body States
5. 5. The Ultra-Processed Food Pipeline
6. 6. Psychedelics and the Default Mode Network
7. 7. The Biopsychosocial Model: Still Radical After All These Years
8. 8. The Funding Gap and the Structure of Neglect
9. 9. What This Means in Practice
10. 10. Conclusion: The Same Fire

Appendices

• A. Source Verification and Confidence Ratings
• B. Bibliography
• C. Cross-References to Related OMXUS Research

Chapter 1: The Serotonin Story Falls Apart

For thirty years, the public explanation for depression has gone something like this: your brain doesn't make enough serotonin, and SSRIs fix that. It was on posters in GP waiting rooms. It was in pharmaceutical ads. It was what your doctor said when they wrote the prescription. It felt scientific. It felt settled.

It wasn't.

In 2022, Joanna Moncrieff and colleagues published an umbrella review in Molecular Psychiatry that did what no single study could do on its own: it gathered every major line of evidence for the serotonin deficit hypothesis of depression and examined them together. The paper reviewed systematic reviews and meta-analyses covering tens of thousands of participants. It looked at serotonin levels in blood and cerebrospinal fluid. It looked at serotonin metabolites. It looked at serotonin receptor binding. It looked at tryptophan depletion studies. It looked at the serotonin transporter gene (5-HTTLPR) and its interaction with stress.

The result was unambiguous. There is no consistent evidence that people with depression have lower serotonin activity than people without depression. The serotonin deficit hypothesis, as a causal explanation for depression, is not supported by the evidence.

This needs to be stated carefully because it has been widely misunderstood. Moncrieff did not claim that SSRIs don't work. She did not say that people should stop taking their medication. What she showed is that the mechanism — the story about low serotonin causing depression — has no consistent empirical support. SSRIs do something. They alter brain chemistry. Some people feel better on them, and that effect is real. But the reason they help (when they help) is probably not because they're correcting a serotonin deficit. It may be neuroplasticity effects, emotional blunting that provides temporary relief, placebo response amplified by the ritual of medical treatment, or something else entirely.

The distinction matters enormously. If SSRIs work by fixing a chemical imbalance, then depression is a hardware problem and drugs are the logical fix. If the chemical imbalance story is wrong, then we have to ask harder questions: what is actually happening in the bodies and lives of depressed people, and what would actually help?

The Moncrieff paper landed in a field that was already uncomfortable. Many researchers had known for years that the serotonin story was oversimplified at best. Irving Kirsch's meta-analyses had shown that the clinical advantage of SSRIs over placebo was modest — often below the threshold for clinical significance — except in the most severely depressed patients (Kirsch et al., 2008). But the serotonin deficit hypothesis had a social function: it destigmatised depression by framing it as a biological illness ("it's not your fault, it's your brain chemistry"), and it gave pharmaceutical companies a clean narrative for marketing. Dismantling the hypothesis doesn't mean depression isn't real or isn't biological. It means the biology is more complex than a single neurotransmitter deficit.

1.1 What Moncrieff Actually Showed

It is worth being precise about the specific findings, because the paper has been both celebrated and distorted:

• Serotonin levels: No consistent difference between depressed and non-depressed populations in blood or cerebrospinal fluid serotonin or its metabolites.
• Serotonin receptor binding: No consistent pattern of altered serotonin receptor density or binding in depressed patients.
• Tryptophan depletion: Experimentally lowering tryptophan (the serotonin precursor) does not reliably induce depression in healthy volunteers, and findings in remitted depressed patients on SSRIs are inconsistent.
• 5-HTTLPR gene: The serotonin transporter gene, once considered strong evidence for a genetic basis of serotonin vulnerability, showed no reliable association with depression in well-powered studies. Earlier positive findings were likely underpowered false positives.
• Long-term SSRI effects: Chronic SSRI use may actually lower serotonin levels through receptor downregulation — the opposite of what the deficit hypothesis would predict.

The paper is published in Molecular Psychiatry (Nature group), peer-reviewed, and has accumulated over 1,400 citations as of early 2026. The findings have been broadly accepted within psychiatry, though debate continues about framing and implications.

1.2 What Moncrieff Did NOT Say

This matters because the paper has been weaponised by people with agendas on both sides:

• She did NOT say SSRIs don't work. She said the reason they were thought to work (correcting a serotonin deficit) is unsupported. These are different claims.
• She did NOT say people should stop taking SSRIs. She has been explicit about this.
• She did NOT say depression is not biological. She said this particular biological explanation is not supported by evidence.
• "Moncrieff proved antidepressants are useless" is FALSE.
• "Depression is all in your head / not real" is NOT what the paper implies.
• "This means depression is purely social/psychological" is NOT implied. The inflammatory hypothesis, which Moncrieff's work is compatible with, is thoroughly biological.

So if it's not a serotonin problem, what is it?

Chapter 2: Depression as Inflammation

One of the most productive lines of research in the last two decades has reframed depression not as a neurotransmitter deficit but as a systemic inflammatory condition. The core observation is straightforward: people with depression, as a group, show elevated levels of inflammatory markers in their blood. C-reactive protein (CRP), interleukin-6 (IL-6), and tumour necrosis factor alpha (TNF-alpha) are consistently higher in depressed populations compared to non-depressed controls.

Michael Berk and colleagues laid out this argument in a landmark 2013 review in BMC Medicine titled "So depression is an inflammatory disease, but where does the inflammation come from?" The paper didn't just document the correlation between inflammation and depression — it traced the pathways. Chronic stress activates the hypothalamic-pituitary-adrenal (HPA) axis, which drives cortisol production, which over time dysregulates immune function and promotes chronic low-grade inflammation. That inflammation crosses the blood-brain barrier, activates microglia (the brain's immune cells), and disrupts neurotransmitter metabolism. Inflammation also diverts tryptophan away from serotonin production and toward the kynurenine pathway, which produces neurotoxic metabolites. So serotonin levels can drop in depression — but not because of a primary serotonin deficit. They drop as a downstream consequence of inflammation.

This reframing is powerful because it connects depression to the rest of medicine. Chronic inflammation is implicated in cardiovascular disease, type 2 diabetes, autoimmune conditions, and cancer. Depressed people have higher rates of all of these. That's not a coincidence — it's the same underlying process manifesting in different organ systems.

2.1 The Inflammatory Subtype

Precision matters here. Not all depressed people show elevated inflammatory markers. The research suggests that inflammation-driven depression is a subtype — a significant one, possibly representing a third to a half of all major depression cases, but not the whole picture. Some depressed people have normal CRP and IL-6. Their depression may have different drivers: trauma, grief, social isolation, learned helplessness, chronic pain, or endocrine disruption. The inflammatory hypothesis doesn't replace the serotonin hypothesis with another single cause. It adds a well-evidenced biological pathway to a condition that is genuinely multi-causal.

Estimates of the inflammatory subtype vary across studies:

• Some research suggests 25-50% of depressed patients show elevated CRP (>3 mg/L).
• The distributions of inflammatory markers in depressed and non-depressed populations overlap substantially. Elevated mean levels do not mean every depressed individual is inflamed.
• There is emerging evidence that the inflammatory subtype responds differently to treatment: patients with high CRP may respond less well to SSRIs and better to anti-inflammatory augmentation.

Saying "depression IS an inflammatory disease" (as Berk's 2013 title provocatively suggests) overstates the case. More accurate: inflammation is a significant driver of depression in a substantial subtype. This paper maintains that nuance throughout. But a substantial subtype is not a marginal curiosity. If a third to a half of all major depression — the leading cause of disability worldwide — has measurable inflammatory biology, that changes clinical practice, research priorities, and how we think about the environmental conditions that generate inflammation.

2.2 Where Does the Inflammation Come From?

Berk et al. (2013) traced multiple sources:

• Chronic psychological stress: HPA axis activation, cortisol dysregulation, immune suppression followed by inflammatory rebound.
• Diet: Western dietary patterns high in refined sugars, processed meats, and ultra-processed foods are pro-inflammatory. Mediterranean dietary patterns are anti-inflammatory and associated with ~30% lower depression risk in meta-analyses.
• Gut permeability: Disruption of the intestinal barrier ("leaky gut") allows bacterial endotoxins (lipopolysaccharides) to enter the bloodstream, triggering systemic immune activation. Evidence is growing but this area is still developing.
• Obesity: Adipose tissue is metabolically active and produces pro-inflammatory cytokines (adipokines). The obesity-depression association may be partly mediated by shared inflammation.
• Sedentary behaviour: Physical inactivity is pro-inflammatory. Exercise is anti-inflammatory.
• Sleep deprivation: Sleep loss elevates cortisol, CRP, and IL-6. Sleep fragmentation is a consistent finding in both depression and inflammatory conditions.
• Smoking: Directly pro-inflammatory and independently associated with depression risk.
• Social isolation: Loneliness drives inflammatory gene expression through the conserved transcriptional response to adversity (CTRA) — upregulation of pro-inflammatory genes, downregulation of antiviral genes. The same inflammatory markers (CRP, IL-6) elevated in depression are elevated in chronic loneliness.

Notice the pattern. These are not random risk factors. They are features of modern life. They are features of a system that confines people to sedentary work for excessive hours, feeds them inflammatory food because it's cheap, isolates them from community because there's no time or structure for connection, deprives them of sleep because the anxiety of precarious employment follows them to bed, and then tells them the resulting depression is a chemical imbalance in their brain.

The inflammation is not coming from nowhere. It is coming from the way we live. And the way we live is not an accident. It is an economic structure.

2.3 The Clinical Implication

If a substantial subgroup of depressed people have measurable inflammation, then anti-inflammatory interventions should help them. And the evidence says they do:

• Exercise: One of the most robustly supported interventions for depression. A 2023 umbrella review by Singh et al. found effect sizes comparable to SSRIs for mild-to-moderate depression. Exercise is profoundly anti-inflammatory — it reduces CRP, IL-6, and TNF-alpha. Herman Pontzer's metabolic reallocation model offers a mechanism: exercise shifts metabolic energy away from inflammatory processes and toward physical repair and immune regulation.
• Omega-3 fatty acids: Anti-inflammatory. Show modest but real antidepressant effects in meta-analyses, with EPA (eicosapentaenoic acid) showing more consistent effects than DHA.
• Mediterranean-style diet: Rich in vegetables, fish, olive oil, and low in processed food. Associated with lower depression risk in prospective studies. The SMILES trial (Jacka et al., 2017) was one of the first RCTs to show dietary intervention improving depression outcomes.
• Sleep restoration: Reduces inflammatory markers. Cognitive behavioural therapy for insomnia (CBT-I) has antidepressant effects that may be partly mediated by reduced inflammation.
• Social connection: Measurable anti-inflammatory effects through reduced CTRA gene expression.
• Curcumin: Anti-inflammatory compound from turmeric. Small but positive RCT evidence for depression augmentation.

This is not alternative medicine. This is what the evidence actually shows when you follow it without a pharmaceutical sales target in mind.

Chapter 3: The Gut-Brain Axis — Where Most of Your Serotonin Actually Lives

Here is a fact that should restructure how you think about mental health: approximately 95% of the body's serotonin is produced not in the brain, but in the gut. Specifically, it's produced by enterochromaffin cells in the intestinal lining. Michael Gershon documented this in his work on the enteric nervous system — what he called "the second brain" — the vast neural network embedded in the walls of the gastrointestinal tract, containing somewhere around 500 million neurons.

This is not a metaphor. The gut has its own nervous system that can operate independently of the brain. It regulates motility, secretion, and blood flow. It communicates with the brain via the vagus nerve — the longest cranial nerve in the body, running from the brainstem to the abdomen. And that communication is bidirectional. The brain talks to the gut (which is why stress gives you a stomach ache), and the gut talks to the brain (which is why gut infections can cause anxiety and mood disturbance).

3.1 Bacterial Regulation of Serotonin

In 2015, Jessica Yano and colleagues at Caltech published a paper in Cell that added a critical piece. They showed that indigenous spore-forming bacteria in the gut — primarily Clostridia species — regulate serotonin biosynthesis in enterochromaffin cells. When these bacteria were absent (in germ-free mice), serotonin production dropped by about 60%. When they were reintroduced, serotonin levels recovered. The bacteria weren't producing serotonin themselves — they were signalling to host cells to produce it, through metabolites including short-chain fatty acids and secondary bile acids.

The implications cascade. If gut bacteria regulate serotonin production, and if serotonin is involved in mood regulation (even if not through the simple deficit model), then the composition of your gut microbiome is relevant to your mental health. And your gut microbiome is shaped by what you eat, what antibiotics you've taken, how you were born (vaginal delivery vs. caesarean), whether you were breastfed, and the microbial environment you grew up in.

3.2 An Important Nuance: Two Serotonin Systems

The 95% figure requires careful interpretation. It refers to the distribution of total body serotonin, not to serotonin's role in mood specifically. Brain serotonin and gut serotonin are functionally separate pools because serotonin does not cross the blood-brain barrier. Brain serotonin is synthesised locally in the raphe nuclei.

The connection between gut serotonin and brain function is therefore indirect. It operates through:

• Vagal signalling: Gut serotonin activates vagal afferent neurons, which carry information to the brainstem and influence mood-related circuits.
• Tryptophan metabolism: Gut inflammation and bacterial metabolites influence the availability of tryptophan (the serotonin precursor) for brain serotonin synthesis. The kynurenine pathway diverts tryptophan toward neurotoxic metabolites when inflammation is present.
• Bacterial metabolites: Short-chain fatty acids, secondary bile acids, and other microbial products cross the blood-brain barrier and influence neuroinflammation, neurotransmitter production, and microglial activation.

The gut-brain connection is real, evidence-based, and mechanistically plausible. But it is not "gut serotonin directly controls your mood." It is a multi-step pathway involving microbial ecology, immune signalling, metabolite trafficking, and neural communication. The literature review is careful about this, and the unified thesis maintains that precision.

3.3 Psychobiotics and the Microbiome-Mood Connection

John Cryan and Ted Dinan at University College Cork have been at the forefront of this work. Their 2012 review in Nature Reviews Neuroscience, "Mind-altering microorganisms," pulled together the evidence that gut bacteria influence brain development, stress reactivity, anxiety-like behaviour, and social behaviour in animal models. The following year, Dinan, Stanton, and Cryan coined the term "psychobiotics" — for probiotics that have mental health effects — in a 2013 paper in Biological Psychiatry. Since then, human trials have shown modest but real effects of certain probiotic strains on anxiety and depression scores, though the field is still young and effect sizes are small.

The most compelling evidence for the causal direction — gut to brain, not just brain to gut — comes from faecal microbiota transplant (FMT) studies. When gut microbiota from depressed humans are transplanted into germ-free rodents, the recipient animals develop depression-like and anxiety-like behaviours. When microbiota from healthy donors are transplanted, behaviours normalise. This is as close to causal evidence as the field currently has, and it points firmly toward the gut as a driver, not merely a passive recipient, of mood states.

3.4 The Vagus Nerve: The Body's Information Highway

Sigrid Breit and colleagues reviewed the vagus nerve's role in a 2018 paper in Frontiers in Psychiatry, documenting how vagal tone — the activity level of the vagus nerve — correlates with emotional regulation, social engagement, and resilience to stress. Low vagal tone is associated with depression, anxiety, and inflammatory conditions. Vagus nerve stimulation (VNS) is FDA-approved for treatment-resistant depression, though its mechanisms are still being worked out. The vagus nerve carries information about gut state, immune status, and inflammatory load directly to the brainstem, which feeds into the circuits that generate mood and emotion.

What this means practically: the state of your gut — its microbial composition, its inflammatory status, its permeability — is not separate from your mental health. It is part of the same system.

Chapter 4: Emotions as Body States — Damasio's Somatic Marker Hypothesis

Antonio Damasio's 1994 book Descartes' Error made an argument that still hasn't fully penetrated clinical practice: emotions are not things that happen in the brain and then get sent to the body. Emotions are body states — or more precisely, they are the brain's representation of body states.

Damasio studied patients with damage to the ventromedial prefrontal cortex — the part of the brain that integrates body-state information into decision-making. These patients had intact intelligence, memory, and language. They could reason through problems logically. But they couldn't make good decisions in real life. They'd make disastrous financial choices, destroy relationships, and fail to learn from experience. The missing piece was what Damasio called "somatic markers" — the gut feelings, the bodily intuitions, the emotional weighting that tells you something is a bad idea before you can articulate why.

The implication for depression is profound. If emotions are body-state representations, then a body in a chronic state of inflammation, gut dysbiosis, sleep deprivation, and physical inactivity is going to generate emotional states that reflect that physical reality. You don't just feel depressed in your brain. You feel depressed in your whole body, because depression is a whole-body state. Treating it as a brain-only problem — adjusting neurotransmitters while ignoring the body that generates the signals those neurotransmitters carry — is like trying to fix a thermometer reading by putting the thermometer in ice water.

Damasio's work is part of a broader movement in cognitive science called embodied cognition — the recognition that the mind is not a computer sitting inside a skull, but a process that emerges from the interaction of brain, body, and environment. This isn't philosophical hand-waving. It has direct clinical implications. If emotion is embodied, then body-based interventions (exercise, diet, sleep, yoga, breathwork, cold exposure) aren't supplementary to mental health treatment. They're addressing the actual substrate.

4.1 The Thermometer Analogy

This is worth sitting with. The biomedical model of depression treats the brain as the site of the problem and pharmaceuticals as the fix. But if Damasio is right — and the neuroscience broadly supports him — then the brain is reporting, not malfunctioning. A brain attached to an inflamed body, a dysbiotic gut, a cortisol-flooded bloodstream, and a socially isolated organism is supposed to generate distress signals. That's what brains do. They represent the state of the body and the environment. Depression, in this framing, is not an error in the representation. It is an accurate representation of a body under siege.

This does not mean depression is useful or desirable. Pain is also an accurate representation — it tells you something is wrong — but chronic pain is still suffering that needs addressing. The point is that addressing it by numbing the signal (SSRIs, in some cases) without changing the conditions that generate the signal is treating the thermometer, not the temperature.

Chapter 5: The Ultra-Processed Food Pipeline

This chapter connects the inflammatory model of depression to the food system. It is where the gut-brain axis research meets food toxicology, and where individual mental health becomes inseparable from food policy.

5.1 Ultra-Processed Food and Depression: The Dose-Response

The epidemiological evidence is now substantial. Multiple large prospective cohort studies have found that ultra-processed food (UPF) consumption — as classified by the NOVA system — is associated with increased risk of depression in a dose-dependent manner. Higher UPF intake, higher depression risk. This association persists after adjusting for total caloric intake, BMI, physical activity, and socioeconomic status.

The mechanisms are the ones this paper has been tracing:

• Gut microbiome disruption: Emulsifiers commonly used in processed food (polysorbate 80, carboxymethylcellulose) have been shown to disrupt the gut mucosal barrier and alter microbiome composition in animal models (Chassaing et al., 2015, Nature). A disrupted mucosal barrier increases intestinal permeability, allowing bacterial endotoxins into the bloodstream, triggering systemic inflammation.
• Dietary AGEs (Advanced Glycation End-products): Formed during high-temperature processing of food (frying, grilling, roasting). AGEs bind to the RAGE receptor, activating the NF-kB signalling pathway, which drives production of the same pro-inflammatory cytokines — CRP, IL-6, TNF-alpha — elevated in depression. The AGE-RAGE-NF-kB axis is the same inflammatory cascade implicated in cardiovascular disease, diabetes, and cancer.
• Nutrient displacement: UPF displaces whole foods that contain anti-inflammatory compounds: omega-3 fatty acids, polyphenols, fibre (which feeds beneficial gut bacteria), vitamins, and minerals.
• Additive load: The cumulative exposure to preservatives, artificial sweeteners, colourings, and flavour enhancers — many of which have limited long-term safety data — creates an additive burden that the precautionary principle should address but currently does not.

5.2 The Precautionary Principle Inverted

In most regulatory domains, the burden of proof works like this: if you want to release a new pharmaceutical, you must prove it is safe and effective through randomised controlled trials before it reaches patients. This is the precautionary principle applied to medicine.

In food regulation, the burden is inverted. Additives, processing methods, and novel ingredients are permitted unless proven harmful. The proof of harm typically requires decades of consumption, accumulated epidemiological evidence, and intense political pressure against industry lobbying — by which point millions of people have already been exposed.

This is not a theoretical concern. Bisphenol A (BPA), trans fats, certain artificial colourings, and multiple pesticides were all considered safe, used widely for years or decades, and only restricted after the evidence of harm became overwhelming. The question is not whether the current food supply contains harmful substances. The question is which ones, and how long before the evidence is considered sufficient.

Goal 10 — "Food contains only things proven safe" — applies the same standard to food that we already apply to pharmaceuticals. If a substance has not been proven safe through rigorous, independent, long-term study, it does not go in food. This is not radical. It is the standard we already use for drugs. We just don't apply it to the thing people consume three times a day, every day, for their entire lives.

5.3 The Economics of Inflammation

Ultra-processed food is cheap. Whole food is expensive. This is not an accident of nature — it is a product of agricultural subsidies, supply chain design, and corporate consolidation. The people most likely to eat pro-inflammatory diets are the people least able to afford anti-inflammatory alternatives. Depression rates are highest in low-income populations. The inflammatory model of depression predicts exactly this: the people most exposed to inflammatory conditions — bad food, precarious work, poor sleep, social isolation, environmental toxins — are the people most likely to develop inflammatory depression.

This is why framing depression as a "chemical imbalance" is not just scientifically wrong. It is politically convenient. It locates the problem inside the individual brain and prescribes an individual solution (a pill). It asks nothing of the food system, the labour market, the housing market, or the social architecture. The inflammatory model, by contrast, is inconvenient. It says: the depression is coming from outside the brain. It is coming from the food, the work, the isolation, the built environment. Fixing it requires changing systems, not just prescribing drugs.

Chapter 6: Psychedelics and the Default Mode Network

Robin Carhart-Harris, first at Imperial College London and later at UC San Francisco, has produced some of the most striking neuroscience of the past decade. Using fMRI, he showed that psilocybin — the active compound in psychedelic mushrooms — disrupts the default mode network (DMN), a set of brain regions that are active during rest, self-referential thinking, and mind-wandering.

In a 2012 paper in PNAS, Carhart-Harris and colleagues showed that psilocybin decreased activity in the DMN hubs — particularly the medial prefrontal cortex and posterior cingulate cortex. This was counterintuitive. The subjective experience of psychedelics is one of expansion, richness, and intensity. You'd expect brain activity to increase. Instead, the regions that decreased were those associated with the ego, the autobiographical self, the internal narrator.

In depression, the DMN is often hyperactive. The depressed brain is a brain stuck in self-referential rumination — the same circuits replaying the same painful narratives, over and over. Carhart-Harris proposed that psilocybin breaks this pattern by temporarily dissolving the rigid self-referential processing that maintains depressive states. It's not that psilocybin makes you happy. It's that it disrupts the neural habits that keep you stuck.

6.1 The Clinical Evidence

The clinical results have been remarkable:

• Carhart-Harris et al. (2016), The Lancet Psychiatry: Open-label feasibility study. 12 patients with treatment-resistant depression — people who had failed multiple antidepressants. All 12 showed reduced depression scores at one week. At three months, 5 of 12 were still in remission. For a treatment-resistant population, those numbers are extraordinary.

• Goodwin et al. (2022), New England Journal of Medicine: COMPASS Pathways Phase 2b trial, the largest psilocybin trial for depression to date, with 233 participants. A single 25mg dose produced significant reductions in depression scores at three weeks compared to a 1mg control dose. The effect attenuated over time and side effects were notable, including suicidal ideation in some participants.

• Carhart-Harris group (2024), UCSF Phase 2: Compared psilocybin to escitalopram (an SSRI) over six weeks. Found comparable efficacy but with psilocybin producing faster onset and greater subjective well-being improvements.

• FDA status: Breakthrough therapy designation granted (2018, to COMPASS Pathways). Phase 3 trials ongoing. Full approval not yet granted as of early 2026.

6.2 Cautions

The evidence is serious and growing, but caution is warranted:

• Sample sizes remain small compared to SSRI trials (hundreds vs. tens of thousands).
• Blinding is a known problem. Participants can often tell whether they received psilocybin or placebo, which may inflate effect sizes through expectancy.
• Adverse events are real. Psilocybin is not a harmless intervention. It requires psychological support, screening for psychotic spectrum conditions, and careful set-and-setting management.
• Media coverage has outpaced the evidence base. There is a hype cycle risk.

6.3 The Inflammation Connection

The psychedelic research connects back to inflammation through an unexpected route: psilocybin and other classical psychedelics have anti-inflammatory properties. They bind to serotonin 2A receptors, which are involved in immune regulation, and there's preliminary evidence that psychedelic experiences reduce inflammatory markers. The mystical or ego-dissolving experiences that correlate with therapeutic benefit may partly work by interrupting the stress-inflammation-depression cycle at a neural level.

This also connects to drug policy. Goal 7 — "Legalise drugs. Stock pharmacies. Cheap." — is not only about decriminalisation of recreational use. It is about removing the legal barriers that have delayed psychedelic research by decades. Psilocybin was a Schedule I substance for over 50 years — classified as having no accepted medical use and high abuse potential. This classification was not based on evidence. It was based on politics. The Portugal model (80% fewer overdose deaths after decriminalisation) demonstrates that drug policy based on health rather than punishment produces better outcomes. The same principle applies to research access.

Chapter 7: The Biopsychosocial Model — Still Radical After All These Years

In 1977, George Engel published a paper in Science called "The Need for a New Medical Model: A Challenge for Biomedicine." He argued that the biomedical model — disease as purely biological dysfunction — was inadequate for understanding illness, particularly mental illness. He proposed the biopsychosocial model: health and disease emerge from the interaction of biological, psychological, and social factors, none of which can be reduced to the others.

Nearly fifty years later, the biopsychosocial model is universally cited and rarely practiced. Medical education mentions it. Clinical guidelines reference it. But the actual delivery of mental health care remains overwhelmingly biomedical: diagnose, prescribe, review medication. The psychological and social dimensions — trauma history, housing stability, employment, social connection, meaning, purpose — are acknowledged in theory and undertreated in practice. Not because clinicians don't care, but because the system is structured around pharmaceutical intervention as the primary tool.

7.1 Why the Model Has No Teeth

This isn't a conspiracy. It's an economic structure. Pharmaceutical companies fund research, medical education, and clinical guidelines. They don't fund parks, community centres, or reduced working hours. The treatments that get studied are the treatments that someone can sell. Exercise is arguably the single most effective intervention for mild to moderate depression — it has antidepressant effects comparable to SSRIs, plus anti-inflammatory effects, plus cardiovascular benefits, plus no withdrawal symptoms. But nobody makes money when you go for a run.

Engel's model has been criticised too. Nassir Ghaemi argued in 2009 that the biopsychosocial model, as practised, has become a vague eclecticism — clinicians claim to address all three dimensions while actually defaulting to whatever they're most comfortable with. The model needs teeth: specific, testable claims about how biological, psychological, and social factors interact in particular conditions.

The inflammatory hypothesis of depression is exactly this — a specific mechanism linking social stress (psychological/social) to immune activation (biological) to mood disturbance (psychological) to further social withdrawal (social), in a measurable, testable cycle. It gives the biopsychosocial model its first real mechanism. It says: here is how the social becomes biological. Here is how loneliness becomes inflammation. Here is how bad food becomes depression. Here is how the environment gets under the skin.

Chapter 8: The Funding Gap and the Structure of Neglect

Mental health conditions account for roughly 20% of the global disease burden, measured in disability-adjusted life years (DALYs). They receive approximately 9-10% of health budgets in high-income countries, and far less in low-income settings. The WHO has documented this gap repeatedly. In the UK, mental health spending has increased in absolute terms but has not kept pace with demand. NHS waiting times for psychological therapies stretched to months, sometimes over a year for specialist services, through the early 2020s.

This underfunding has consequences beyond individual suffering. Depression is a leading cause of disability worldwide. It reduces productivity, strains relationships, increases physical health costs (through the inflammation link), and is a major driver of suicide. The economic case for adequate mental health funding is overwhelming — the WHO estimates a 4:1 return on investment in depression and anxiety treatment. But the funding doesn't follow the evidence because mental health doesn't have the political immediacy of, say, cancer or cardiac surgery.

8.1 The Irony

The irony, given what this review covers, is that depression and cancer may share more common ground than their separate funding streams suggest. Chronic inflammation drives both. Social isolation worsens both. Exercise helps prevent both. Diet matters for both. If the research funding reflected the biology rather than the disease categories, we'd see far more integrated research on the shared inflammatory pathways that underlie what we currently treat as unrelated conditions.

Instead, we have oncology and psychiatry in separate buildings, with separate budgets, studying the same inflammatory pathways in isolation, publishing in separate journals, and competing for the same shrinking pool of public research funding — while pharmaceutical companies fund the research that leads to patentable molecules and ignore the research that leads to parks, cooking classes, and four-day work weeks.

8.2 The Structural Alternative

Goal 2 — "Work 22 hours max. Keep your pay. Choose your hours. Work from home." — is a mental health intervention. Not metaphorically. Biologically. Reducing work hours reduces chronic stress, which reduces HPA axis activation, which reduces cortisol, which reduces inflammation, which reduces depression risk. The extra time allows for exercise, cooking, social connection, and sleep — all of which are anti-inflammatory.

Goal 11 — "Monkey bars at every bus stop. Climbing walls on all stairwells." — is a mental health intervention. Exercise reduces inflammatory markers. Physical environments designed for movement reduce sedentary behaviour. Bodies that move are less inflamed. Brains attached to less-inflamed bodies generate fewer distress signals.

Goal 13 — "Press it, your people come in 60 seconds." — is a mental health intervention. Social connection reduces CTRA inflammatory gene expression. A network of people who show up physically, in person, in under a minute, is the opposite of the social isolation that drives inflammation.

These goals are not separate from mental health policy. They ARE mental health policy. The inflammatory model of depression makes this legible: the conditions that generate inflammation generate depression. Change the conditions, change the inflammation, change the depression.

Chapter 9: What This Means in Practice

If you pull together everything in this paper, a picture emerges that is both more complex and more hopeful than the serotonin story.

Depression — or at least a large, clinically significant subtype of depression — involves systemic inflammation. That inflammation can originate from chronic stress, poor diet, gut dysbiosis, sleep deprivation, sedentary lifestyle, social isolation, or some combination. It disrupts neurotransmitter metabolism, activates brain immune cells, and maintains a body state that the brain represents as depressed mood.

The gut-brain axis is a central pathway. The gut produces most of the body's serotonin, and gut bacteria regulate that production. The vagus nerve carries information about gut state and immune status directly to the brain. A dysbiotic, inflamed gut generates signals that promote depression. A healthy, diverse gut microbiome generates signals that protect against it.

Emotions are body states, not abstract mental events. A body in chronic inflammation and dysregulated stress response will generate emotions that reflect that state. Treating the body is treating the mind.

Psychedelics may offer a way to break rigid neural patterns that maintain depression, particularly the DMN hyperactivity associated with rumination. This is still early-stage but the evidence is serious and growing.

9.1 The Evidence-Based Intervention Stack

Front-line treatment for the inflammatory subtype of depression should include anti-inflammatory interventions alongside or instead of SSRIs:

These aren't lifestyle tips. They're interventions targeting specific, measurable biological pathways. The evidence base for exercise as an antidepressant is now comparable to the evidence base for SSRIs — with the additional advantage of no withdrawal effects, cardiovascular benefit, and anti-inflammatory action.

9.2 What Front-Line Care Should Look Like

Instead of: GP appointment -> depression screening questionnaire -> SSRI prescription -> review in 6 weeks.

Consider: GP appointment -> depression screening + CRP blood test -> if elevated CRP, prioritise anti-inflammatory interventions (exercise prescription, dietary assessment, sleep assessment, social prescribing) alongside or before SSRIs -> gut health assessment if indicated -> review in 4 weeks with inflammatory marker tracking.

This is not anti-pharmaceutical. SSRIs help some people and nobody should be told to stop medication without medical guidance. This is anti-monopoly. The pharmaceutical intervention should not be the only tool in the kit when the evidence supports multiple effective interventions targeting the same biology.

Chapter 10: Conclusion — The Same Fire

The serotonin story was simple and wrong. The real story is more complex and more useful. It tells us that mental health is not separate from physical health, that the body is not separate from the mind, and that the way we organise society is not separate from the diseases we get.

Depression and cancer share inflammatory biology. Depression and cardiovascular disease share inflammatory biology. Depression and diabetes share inflammatory biology. These are not four diseases. They are four expressions of one underlying process: chronic systemic inflammation driven by environmental conditions — food, stress, isolation, sedentary confinement, toxic exposures, sleep deprivation.

A society that redesigns its food systems (Goal 10) is preventing depression. A society that reduces work hours (Goal 2) is preventing depression. A society that builds physical environments for movement (Goal 11) is preventing depression. A society that creates emergency community response networks (Goal 13) is preventing depression. A society that legalises and researches psychedelic medicines (Goal 7) is treating depression. A society that applies the precautionary principle to food additives is preventing the gut dysbiosis that drives the inflammation that drives the depression that drives the disability that costs the economy more than the prevention would have.

This is not a metaphor. These are measurable biological pathways, documented in peer-reviewed research, replicated across populations, and mechanistically understood at the molecular level.

The woman in the GP's office is not broken. Her brain is not malfunctioning. Her body is in a state of chronic inflammatory emergency generated by the food she can afford, the hours she works, the sleep she can't get, the connections she's lost, and the built environment that keeps her sedentary. Her depression is her body telling the truth.

The question is not what's wrong with her. The question is what's wrong with the system that made her sick and then sold her a pill for it.

Appendix A: Source Verification and Confidence Ratings

Critical Distinctions

Moncrieff et al. (2022) — What it actually says

What Moncrieff showed:

• No consistent evidence that serotonin levels, metabolite levels, receptor binding, or transporter activity differ between depressed and non-depressed populations.
• The 5-HTTLPR gene showed no reliable association with depression in well-powered studies; earlier positive findings were likely underpowered.
• Long-term SSRI use may actually lower serotonin levels (downregulation) — the opposite of what the deficit hypothesis predicts.

What Moncrieff did NOT say:

• She did NOT say SSRIs don't work. Mechanism =/= efficacy.
• She did NOT say people should stop taking SSRIs.
• She did NOT say depression is not biological.

Verification status: Published in Molecular Psychiatry (Nature group), peer-reviewed, ~1,400+ citations as of early 2026. Findings broadly accepted within psychiatry.

"Not all depression is inflammatory" — Essential Caveat

Meta-analyses find elevated mean inflammatory markers in depressed populations, but distributions overlap substantially. Estimated 25-50% of depressed patients show elevated CRP (>3 mg/L). This is a subtype, not a universal mechanism. The paper maintains this nuance throughout.

95% of Serotonin in the Gut — Source Tracing

The figure originates from Gershon's work (The Second Brain, 1998) and refers to peripheral serotonin distribution. Brain serotonin is synthesised locally and does not cross the blood-brain barrier. The gut-brain connection operates indirectly through vagal signalling, tryptophan metabolism, and bacterial metabolites. The paper is careful about this distinction.

Psilocybin Research — Status as of Early 2026

• FDA breakthrough therapy designation: GRANTED (2018, COMPASS Pathways).
• COMPASS Phase 2b (Goodwin 2022, NEJM): Positive with caveats — effect attenuation, notable adverse events.
• Phase 3 trials: Ongoing. Full FDA approval not yet granted.
• Carhart-Harris at UCSF since ~2021 (Neuroscape psychedelics division).
• Blinding remains a methodological challenge. Sample sizes are small relative to SSRI evidence base.

Confidence Ratings

Appendix B: Bibliography

Primary Sources

1. 1. Moncrieff, J., Cooper, R.E., Stockmann, T., Amendola, S., Hengartner, M.P., & Horowitz, M.A. (2022). "The serotonin theory of depression: a systematic umbrella review of the evidence." Molecular Psychiatry, 27, 3243-3256. https://doi.org/10.1038/s41380-022-01661-0

1. 2. Berk, M., Williams, L.J., Jacka, F.N., O'Neil, A., Pasco, J.A., Moylan, S., Allen, N.B., Stuart, A.L., Hayley, A.C., Byrne, M.L., & Maes, M. (2013). "So depression is an inflammatory disease, but where does the inflammation come from?" BMC Medicine, 11, 200. https://doi.org/10.1186/1741-7015-11-200

1. 3. Yano, J.M., Yu, K., Donaldson, G.P., Shastri, G.G., Ann, P., Ma, L., Nagler, C.R., Ismagilov, R.F., Mazmanian, S.K., & Hsiao, E.Y. (2015). "Indigenous Bacteria from the Gut Microbiota Regulate Host Serotonin Biosynthesis." Cell, 161(2), 264-276. https://doi.org/10.1016/j.cell.2015.02.047

1. 4. Damasio, A. (1994). Descartes' Error: Emotion, Reason, and the Human Brain. New York: G.P. Putnam's Sons.

1. 5. Carhart-Harris, R.L., Erritzoe, D., Williams, T., Stone, J.M., Reed, L.J., Colasanti, A., Tyacke, R.J., Leech, R., Malizia, A.L., Murphy, K., Hobden, P., Evans, J., Feilding, A., Wise, R.G., & Nutt, D.J. (2012). "Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin." Proceedings of the National Academy of Sciences, 109(6), 2138-2143. https://doi.org/10.1073/pnas.1119598109

1. 6. Carhart-Harris, R.L., Bolstridge, M., Rucker, J., Day, C.M.J., Erritzoe, D., Kaelen, M., Bloomfield, M., Rickard, J.A., Forbes, B., Feilding, A., Taylor, D., Pilling, S., Curran, V.H., & Nutt, D.J. (2016). "Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study." The Lancet Psychiatry, 3(7), 619-627. https://doi.org/10.1016/S2215-0366(16)30065-7

1. 7. Goodwin, G.M., Aaronson, S.T., Alvarez, O., Arden, P.C., Baker, A., Bennett, J.C., ... & Malievskaia, E. (2022). "Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression." New England Journal of Medicine, 387(18), 1637-1648. https://doi.org/10.1056/NEJMoa2206443

1. 8. Engel, G.L. (1977). "The Need for a New Medical Model: A Challenge for Biomedicine." Science, 196(4286), 129-136. https://doi.org/10.1126/science.847460

1. 9. Cryan, J.F. & Dinan, T.G. (2012). "Mind-altering microorganisms: the impact of the gut microbiota on brain and behaviour." Nature Reviews Neuroscience, 13(10), 701-712. https://doi.org/10.1038/nrn3346

1. 10. Dinan, T.G., Stanton, C., & Cryan, J.F. (2013). "Psychobiotics: A Novel Class of Psychotropic." Biological Psychiatry, 74(10), 720-726. https://doi.org/10.1016/j.biopsych.2013.05.001

1. 11. Breit, S., Kupferberg, A., Rogler, G., & Hasler, G. (2018). "Vagus Nerve as Modulator of the Brain-Gut Axis in Psychiatric and Inflammatory Disorders." Frontiers in Psychiatry, 9, 44. https://doi.org/10.3389/fpsyt.2018.00044

Secondary and Contextual Sources

1. 11. Kirsch, I., Deacon, B.J., Huedo-Medina, T.B., Scoboria, A., Moore, T.J., & Johnson, B.T. (2008). "Initial Severity and Antidepressant Benefits: A Meta-Analysis of Data Submitted to the Food and Drug Administration." PLoS Medicine, 5(2), e45.

1. 12. Ghaemi, S.N. (2009). "The rise and fall of the biopsychosocial model." British Journal of Psychiatry, 195(1), 3-4.

1. 13. Chassaing, B., Koren, O., Goodrich, J.K., Poole, A.C., Srinivasan, S., Ley, R.E., & Gewirtz, A.T. (2015). "Dietary emulsifiers impact the mouse gut microbiota promoting colitis and metabolic syndrome." Nature, 519(7541), 92-96. https://doi.org/10.1038/nature14232

1. 14. Singh, B., Olds, T., Curtis, R., Dumuid, D., Virgara, R., Watson, A., Szeto, K., O'Connor, E., Ferguson, T., Eglitis, E., Miatke, A., Simpson, C.E.M., & Maher, C. (2023). "Effectiveness of physical activity interventions for improving depression, anxiety and distress: an overview of systematic reviews." British Journal of Sports Medicine, 57(18), 1203-1209. https://doi.org/10.1136/bjsports-2022-106195

1. 15. Jacka, F.N., O'Neil, A., Opie, R., Itsiopoulos, C., Cotton, S., Mohebbi, M., Castle, D., Dash, S., Mihalopoulos, C., Chatterton, M.L., Brazionis, L., Dean, O.M., Hodge, A.M., & Berk, M. (2017). "A randomised controlled trial of dietary improvement for adults with major depression (the 'SMILES' trial)." BMC Medicine, 15(1), 23. https://doi.org/10.1186/s12916-017-0791-y

1. 16. Gershon, M.D. (1998). The Second Brain: A Groundbreaking New Understanding of Nervous Disorders of the Stomach and Intestine. New York: HarperCollins.

1. 17. Pontzer, H. (2021). Burn: New Research Blows the Lid Off How We Really Burn Calories, Lose Weight, and Stay Healthy. New York: Avery.

Appendix C: Cross-References to Related OMXUS Research

This paper does not exist in isolation. The inflammatory model of depression intersects with multiple other research threads in the OMXUS corpus. The connections are not incidental — they reflect the paper's central claim that depression, cancer, cardiovascular disease, and metabolic syndrome share underlying inflammatory biology driven by environmental conditions.

Direct Connections

Indirect Connections

The Convergence Point

Every cross-reference above converges on the same biology: chronic systemic inflammation driven by environmental conditions. The food system inflames you (food toxicology, diet research, AGEs). The work system stresses you (bullshit jobs, cooperative capitalism). The social architecture isolates you (social group scaling, human enclosure). The education system trains compliance into you (Prussian model). The justice system punishes your distress (community policing, drug policy). And the medical system sells you a pill for the inflammation that all of those systems generated.

This is why the 14 goals are not separate policy proposals. They are a single intervention targeting a single underlying process — chronic inflammation — from every direction that generates it.

This paper is part of the OMXUS Research Series. All claims are evidence-based and source-verified. Confidence ratings for each major claim are provided in Appendix A. The authors welcome correction, challenge, and extension.

For correspondence: OMXUS Research, omxus.com